Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02179281
Other study ID # SG-01
Secondary ID
Status Completed
Phase N/A
First received June 28, 2014
Last updated March 9, 2015
Start date October 2014
Est. completion date February 2015

Study information

Verified date March 2015
Source University of Ljubljana, Faculty of Medicine
Contact n/a
Is FDA regulated No
Health authority Slovenia: Slovenian Agency for Drugs and Medical DevicesIsrael: Ministry of Health
Study type Interventional

Clinical Trial Summary

The aim of the study is to prove whether the use of the SmartGuard feature of the MiniMed system significantly reduces hypoglycemic excursions and thus provide proactive protection to the user.


Description:

This is randomized two-arm parallel controlled open label study that will be conducted at two sites, in Slovenia and Israel. It is an investigator initiated pediatric clinical study.

Study will be conducted on pediatric population during two weeks, following a 3 day Run-in period that will allow the patients to get familiar with study device and CGM (SmartGuard OFF).

Patients will be asked to continuously wear the study device for 14 days, which will be set up by study staff according to randomization in the specific group. They will be provided with a diary for entering their daily activity, food consumption (carb count) and eventual adverse events.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date February 2015
Est. primary completion date February 2015
Accepts healthy volunteers No
Gender Both
Age group 8 Years to 18 Years
Eligibility Inclusion Criteria:

- Informed consent signed by a parent/legal guardian and informed assent signed by the study participant prior study entry

- Diagnosed with Type 1 DM at least 12 months prior to signature of Patient Informed Consent (PIC).

- Age between 8-18 years old (inclusive) at signature of PIC

- Treated by CSII with or without CGM at least 3 months prior to signature of PIC, but no use of LGS for last two weeks prior to signature of PIC.

- HbA1c value at screening visit =10%

- Knowledgeable on the use of CSII, administering treatment, adjusting insulin according to diet and exercise

- Performance of an average of four (4) SMBG per day, as evidenced from patient files, or latest insulin pump or glucose meter download

- Treated by the investigator's centre for at least 6 months prior signature of PIC.

- Willing to undergo all study procedures

Exclusion Criteria:

- Hearing or vision impairment so that glucose display and alarms cannot be recognized.

- Alcohol or drug abuse.

- Non-compliance with diabetes self-monitoring and disease management

- Documented cutaneous allergy or disease (allergy to sensor or components of the sensor, psoriasis, staphylococcus, exanthema etc.).

- Any documented concomitant chronic disease known to affect diabetes control (e.g. altered renal function, active cancer undergoing treatment, Crohn's disease, ulcerative colitis, Mb Addison disease) or any concomitant pharmacological treatment that might modify glycemic values (e.g. chronic corticosteroid therapy),

- Eating disorders and morbid obesity (defined as adults: BMI>35 and children BMI > 2 SD for age) as assessed by the investigator.

- Any other medical, social or psychological condition that, in the investigator's opinion, makes the patient unable to comply with the study protocol and all study procedures.

- Patient that does not have a reliable support person.

- Participation in another clinical study, on-going or completed less than 2 months prior to signature of PIC.

- Pregnancy (per investigator judgment, including pregnancy test if necessary)

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention


Intervention

Device:
Medtronic MiniMed™ 640G system
The MiniMed™ 640G system is indicated for the continuous delivery of insulin, for continuous or periodic monitoring of glucose levels in the fluid under the skin, with a feature for a prediction of low or high glucose episodes.

Locations

Country Name City State
Israel Schneider Children's Medical Center of Israel, The Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes Petah Tikva
Slovenia University of Ljubljana, Faculty of Medicine Ljubljana

Sponsors (1)

Lead Sponsor Collaborator
University of Ljubljana, Faculty of Medicine

Countries where clinical trial is conducted

Israel,  Slovenia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Significant between-group difference in number of hypoglycemic events After all patients completed 14 days of study treatment No
See also
  Status Clinical Trial Phase
Completed NCT04476472 - Omnipod Horizon™ Automated Glucose Control System Preschool Cohort N/A
Completed NCT03635437 - Evaluation of Safety and Diabetes Status Upon Oral Treatment With GABA in Patients With Longstanding Type-1 Diabetes Phase 1/Phase 2
Completed NCT04909580 - Decision Coaching for Youth and Parents Considering Insulin Delivery Methods for Type 1 Diabetes N/A
Active, not recruiting NCT00679042 - Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol Phase 3
Completed NCT03293082 - Preschool CGM Use and Glucose Variability in Type 1 Diabetes N/A
Completed NCT04016662 - Automated Insulin Delivery in Elderly With Type 1 Diabetes (AIDE T1D) Phase 4
Completed NCT02527265 - Afrezza Safety and Pharmacokinetics Study in Pediatric Patients Phase 2
Completed NCT03738865 - G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes Phase 3
Completed NCT03240432 - Wireless Innovation for Seniors With Diabetes Mellitus N/A
Completed NCT03168867 - Effectiveness Trial of an E-Health Intervention To Support Diabetes Care in Minority Youth (3Ms) N/A
Completed NCT03674281 - The VRIF Trial: Hypoglycemia Reduction With Automated-Insulin Delivery System N/A
Completed NCT03669770 - Ultrasound Classification and Grading of Lipohypertrophy and Its Impact on Glucose Variability in Type 1 Diabetes
Recruiting NCT03682640 - Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes Phase 2
Recruiting NCT04096794 - Chinese Alliance for Type 1 Diabetes Multi-center Collaborative Research
Completed NCT02882737 - The Impact of Subcutaneous Glucagon Before, During and After Exercise a Study in Patients With Type 1 Diabetes Mellitus N/A
Recruiting NCT02745808 - Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes Phase 1
Completed NCT02562313 - A Trial Investigating the Continuous Subcutaneous Insulin Infusion of a Liquid Formulation of BioChaperone Insulin Lispro in Comparison to Humalog® Phase 1
Completed NCT02596204 - Diabetes Care Transformation: Diabetes Data Registry and Intensive Remote Monitoring N/A
Withdrawn NCT02518022 - How to be Safe With Alcoholic Drinks in Diabetes N/A
Withdrawn NCT02579148 - Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes Phase 1